Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
Open Access
- 18 June 2013
- journal article
- review article
- Published by Elsevier BV in Journal of Gastrointestinal Surgery
- Vol. 17 (11), 1997-2006
- https://doi.org/10.1007/s11605-013-2243-0
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJama-Journal Of The American Medical Association, 2012
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsThe Lancet Oncology, 2011
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysisThe Lancet Oncology, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Risk stratification of patients diagnosed with gastrointestinal stromal tumorHuman Pathology, 2008
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Journal of Surgical Oncology, 2008
- Gastrointestinal stromal tumourThe Lancet, 2007
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002